Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-17-003917
Filing Date
2017-04-17
Accepted
2017-04-14 17:50:34
Documents
57
Period of Report
2016-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm 10-K 856053
2 ex10-4.htm EX-10.4 102825
3 ex10-6.htm EX-10.6 60804
4 ex10-7.htm EX-10.7 62177
5 ex10-8.htm EX-10.8 64550
6 ex31-1.htm EX-31.1 13037
7 ex32-1.htm EX-32.1 6617
8 image_005.jpg GRAPHIC 8199
  Complete submission text file 0001493152-17-003917.txt   3972211

Data Files

Seq Description Document Type Size
9 XBRL INSTANCE FILE endv-20161231.xml EX-101.INS 566463
10 XBRL SCHEMA FILE endv-20161231.xsd EX-101.SCH 42782
11 XBRL CALCULATION FILE endv-20161231_cal.xml EX-101.CAL 41781
12 XBRL DEFINITION FILE endv-20161231_def.xml EX-101.DEF 167535
13 XBRL LABEL FILE endv-20161231_lab.xml EX-101.LAB 302971
14 XBRL PRESENTATION FILE endv-20161231_pre.xml EX-101.PRE 235186
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

EIN.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-55453 | Film No.: 17763342
SIC: 2834 Pharmaceutical Preparations